Press releases
Some non-regulatory announcements are only available in English. All announcements required under applicable law, regulation or code are available in English and Swedish.
2026
27 Aug 2026, 18:45
21 Aug 2026, 07:30 | Regulatory
Lund, Sweden August 21, 2026, Hansa Biopharma AB (publ), Reg. No. 556734-5359 (“Hansa Biopharma”), with registered office in Lund, gives notice to Extraordinary General Meeting to be held on September 22, 2026 at 15.00 CEST at Hansa Biopharma’s office on Scheelevägen 22, SE-223 63 Lund. Registration starts at 14.30 CEST.
21 Aug 2026, 07:00 | Regulatory
18 Aug 2026, 08:00
22 Jul 2026, 07:00 | Regulatory
· €115 million out-licensing agreement
· Positive data from European confirmatory trial (PAES)
8 Jul 2026, 11:30
2 Jul 2026, 13:00
1 Jul 2026, 14:30 | Regulatory
· SERB assumes responsibility for the commercialization of Idefirix in transplantation in the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA region
· The transaction significantly strengthens Hansa’s financial position and enables a robust US launch, subject to US approval of imlifidase